The ANTARES study is testing a medicine called nivolumab on people with rare forms of cancer that have spread or grown despite other treatments. This trial is called a **basket trial** because it focuses on cancers with a similar trait, not where they started. Nivolumab is an antibody that helps the immune system find and fight cancer cells that show a protein called **PD-L1**. The study lasts up to 12 months and aims to discover how well nivolumab works and how safe it is. Only adults with rare cancers that show PD-L1 and have not responded to other treatments can join.
**Key Points:**
- Participants receive treatment for a maximum of 12 months or until the cancer progresses.
- The study takes place at multiple centers and is expected to last four years.
- Participants must agree to use contraception and follow other safety measures during and after the study.
**Eligibility:** Adults 18+, with specific rare cancers showing PD-L1, who haven't responded to other treatments. Conditions like active infection or recent major surgery may exclude participation.
How understandable was the trial content above?
Hard to understand
Easy to understand